Delighted to announce that Epidarex Capital's portfolio company, Kynos Therapeutics, has been acquired by Dr. Falk Pharma of Germany, a global leader in digestive and metabolic medicine. This significant value realisation highlights our continued success in building novel early-stage life science companies focused on major unmet disease needs. Read the full press release here: https://lnkd.in/gHynxUgx
Epidarex Capital
风险投资与私募股权管理人
Bethesda，Maryland 2,831 位关注者
Epidarex is a leading transatlantic venture capital firm focused on building ground-breaking life sciences companies
关于我们
Epidarex Capital is a leading transatlantic venture capital firm that invests in early-stage, high growth life science opportunities in under-ventured markets. Epidarex funds ground-breaking research, often building companies from scratch, to address large unmet medical needs with solutions that provide significant benefits to patients.
- 网站
-
https://www.epidarex.com
Epidarex Capital的外部链接
- 所属行业
- 风险投资与私募股权管理人
- 规模
- 2-10 人
- 总部
- Bethesda，Maryland
- 类型
- 私人持股
- 创立
- 2010
- 领域
- Investment in early-stage, high growth life science and health technology companies
地点
Epidarex Capital员工
动态
-
Curve Therapeutics today announces the appointment of Rab Prinjha as our new Chief R&D Officer. Rab joins from GSK where he was Head of the Immunology Research Unit and Immunology Network sponsor. He is a proven R&D leader with a more than 20-year track record of leading drug discovery programs and collaborations across immunology, oncology, neuroscience and epigenetics. At Curve, he will be responsible for driving the advancement of rich pipeline of first-in-class therapeutic assets. His appointment, alongside our recent appointments of Andre Hoekema and Cora Griffin as Chair of the Board and Head of Business Development respectively, signifies the strong momentum that we have created at Curve as we look to improve patient outcomes by discovering innovative drugs that address the most challenging and complex disease targets. You can read more in the full press release linked in the comments below. ? #appointment #drugdiscovery #neuroscience #biotech ?
-
-
Why is women’s health still an under-ventured market? In this clip Terri Burke, Venture Partner at Epidarex Capital, offers strategic advice for women’s health companies, presents some promising data, and urges everyone to discuss and support women’s health needs to continue driving innovation in this space. Tune into our #LSIUSA24 panel, “Why is Women's Health Still an Under-Ventured Market?”, to hear from the leaders who are investing and innovating in this space. Hear from: ? Holly Scott (Moderator) — The Mullings Group ? Terri Burke — Epidarex Capital ? Tara Ghazi, Ph.D. — MALCOVA ? Todd Usen — CEO, Chairman, Board Director ? Amrish Nair — Biorithm Catch more panels like this at LSI USA ‘25 March 17th - 21st in 2025. Our hotel room block at the Monarch Beach Resort is already nearing capacity, and is expected to sell out well in advance. Secure your spot today to ensure you get the best rate and secure a hotel room onsite before they’re sold out.
-
It's a wrap for LSI Europe in Sintra, Portugal! Check out the amazing pictures of our CEO Ana Maiques taking the stage for the #Neuromodulation panel with other incredible industry leaders like herself, she also had the chance to meet with friends and colleagues from the field! Together with Meron Gribetz, Catherine Poulin-Filion, Melissa Lezameta, and Bálint Várkuti, they had a fascinating discussion about the challenges, ethics, and what is driving innovation and investment in the medtech field. Ana also shared insights on how we're revolutionizing neurotech to improve lives. ?? Congratulations once again to LSI for setting up such a wonderful event! Sectoral Asset Management, Epidarex Capital CereGate Inner Cosmos #Medtech #Healthtech #LSI #Portugal #LSIEurope24
-
-
-
-
-
+2
-
-
We have been granted ‘rare pediatric disease designation’ (RPD) in the US by the Food and Drug Administration (FDA) for our novel investigational therapy, ETD001, designed for the treatment of Cystic Fibrosis (CF). ? The RPD designation was based on the assessment of CF as a serious or life-threatening disease, primarily affecting individuals aged from birth to 18 years. ? Earlier this year we commenced phase 2 clinical trials of ETD001, which aim to assess the safety and efficacy in the 10% of people with CF (pwCF) who are ineligible for or not receiving CTFR modulator therapy. Read the full press release here: https://bit.ly/4eEZt0g
-
-
Great to be at #LSIEurope2024 and see so many exciting technologies! Ana Maiques, Catherine Poulin-Filion, Bálint Várkuti and Meron Gribetz, I really enjoyed sharing the panel on #Neuromodulation with you, thanks for sharing your experience and insights.
-
-
We are thrilled to announce that Epidarex’s Lori Gough has been invited to speak on an esteemed panel at the Life Sciences Pennsylvania annual meeting! Lori will join industry leaders to discuss key takeaways from the conference and provide actionable advice on leveraging new partnerships. Join us in celebrating this incredible achievement and stay tuned for more updates from the event!
-
-
Congratulations to Epidarex portfolio company Harness Therapeutics on their appointment of Dr Paulo Fontoura, as Non-Executive Director. We look forward to working with you!
We are delighted to announce today that Paulo Fontoura is joining our Board as a non-exec-director. Paulo's brings huge breadth and depth of experience in neurological disorders and the development of highly innovative medicines from his time heading up Neuro at Roche. We are looking forwards to working with Paulo as we advance our FAN1 programme for Huntington's towards the clinic and develop our portfolio of first-in-class targets for the huge unmet need in the Neurodegeneration area! https://lnkd.in/e5Uq72gC
-
-
Epidarex Associate Melissa Lezameta is excited to be joining the panel "Neurostimulation: Challenges, Ethics, and Unmet needs driving Innovation" at this year's LSI Europe in Portugal. #LSIEurope24
-
-
Epidarex is pleased to announce the addition of Ryme Medical to our portfolio of medtech investments.?Ryme is?developing a unique catheter-based therapy that seeks to reduce symptoms and improve long-term outcomes in patients suffering with COPD. COPD impacts more than 320 million patients worldwide. As part of this Series A round of financing, Terri Burke, Venture Partner,?will join the board of directors. We are so pleased to be working with our partners at Seroba?Life Sciences?and Santé. #Ryme, Seroba., SANTé, Paul Andreotti, Catello Somma, James Eadie, Victor Pong, PhD, Peter Finan, Kevin Lalande, Fogarty Innovation
-